

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-2. (Cancelled)

3. (Currently Amended) A method of treatment of renal failure-associated metabolic bone disease, comprising administering an effective amount of erythropoietin for said treatment to a patient with renal failure-associated metabolic bone disease.

4. (Previously Presented) The method of treatment according to claim 3, comprising administering erythropoietin in a usual dose of 0.1 to 500 µg, per adult.

5. (Previously Presented) The method of treatment according to claim 3, wherein said patient with said renal failure-associated metabolic bone disease is a patient with renal failure-associated osteodystrophy or renal failure-associated osteoporosis.

Claims 6-7. (Cancelled)

8. (Previously Presented) The method of claim 4 wherein said usual dose is 5 to 100 µg.